Skip to main content

Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).

Publication ,  Journal Article
Ditzel, HM; Strickland, KC; Meserve, EE; Stover, E; Konstantinopoulos, PA; Matulonis, UA; Muto, MG; Liu, JF; Feltmate, C; Horowitz, N; Gupta, M ...
Published in: Int J Gynecol Pathol
May 2019

A chemotherapy response score (CRS) system was recently described to assess the histopathologic response and prognosis of patients with tubo-ovarian high-grade serous carcinoma (HGSC) receiving neoadjuvant chemotherapy. The current study was performed as an independent assessment of this CRS system. We retrospectively identified advanced stage HGSC patients who received neoadjuvant chemotherapy and underwent interval debulking. If available, a hemotoxylin and eosin slide from the omentum and the adnexa was selected for the study. Slides were independently scored by 13 pathologists using the 3-tiered CRS system. Reviewers then received web-based training and rescored the slides. Overall survival and progression-free survival were estimated using the Kaplan-Meier method and compared using the log-rank test. A total of 68 patients with omental (n=65) and/or adnexal (n=59) slides were included in the study. Interobserver reproducibility was moderate for omentum (κ, 0.48) and poor for adnexa (κ, 0.40), which improved for omentum (κ, 0.62) but not for adnexa (κ, 0.38) after online training. For omental slides, a consensus CRS of 1/2 was associated with a shorter median progression-free survival (10.9 mo; 95% confidence interval, 9-14) than a CRS of 3 (18.9 mo; 95% CI, 18-24; P=0.020). In summary, a 3-tiered CRS system of hemotoxylin and eosin-stained omental deposits can yield prognostic information for HGSC patients receiving neoadjuvant chemotherapy, and web-based training improved reproducibility but did not alter determination of clinical outcomes. The CRS system may allow oncologists to identify potential nonresponders and triage HGSC patients for heightened observation and/or clinical trials.

Duke Scholars

Published In

Int J Gynecol Pathol

DOI

EISSN

1538-7151

Publication Date

May 2019

Volume

38

Issue

3

Start / End Page

230 / 240

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Retrospective Studies
  • Prognosis
  • Pathology
  • Ovarian Neoplasms
  • Online Systems
  • Omentum
  • Observer Variation
  • Neoadjuvant Therapy
  • Kaplan-Meier Estimate
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ditzel, H. M., Strickland, K. C., Meserve, E. E., Stover, E., Konstantinopoulos, P. A., Matulonis, U. A., … Howitt, B. E. (2019). Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol, 38(3), 230–240. https://doi.org/10.1097/PGP.0000000000000513
Ditzel, Helena M., Kyle C. Strickland, Emily E. Meserve, Elizabeth Stover, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Michael G. Muto, et al. “Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).Int J Gynecol Pathol 38, no. 3 (May 2019): 230–40. https://doi.org/10.1097/PGP.0000000000000513.
Ditzel HM, Strickland KC, Meserve EE, Stover E, Konstantinopoulos PA, Matulonis UA, et al. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May;38(3):230–40.
Ditzel, Helena M., et al. “Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).Int J Gynecol Pathol, vol. 38, no. 3, May 2019, pp. 230–40. Pubmed, doi:10.1097/PGP.0000000000000513.
Ditzel HM, Strickland KC, Meserve EE, Stover E, Konstantinopoulos PA, Matulonis UA, Muto MG, Liu JF, Feltmate C, Horowitz N, Berkowitz RS, Gupta M, Hecht JL, Lin DI, Jochumsen KM, Welch WR, Hirsch MS, Quade BJ, Lee KR, Crum CP, Mutter GL, Nucci MR, Howitt BE. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May;38(3):230–240.

Published In

Int J Gynecol Pathol

DOI

EISSN

1538-7151

Publication Date

May 2019

Volume

38

Issue

3

Start / End Page

230 / 240

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Retrospective Studies
  • Prognosis
  • Pathology
  • Ovarian Neoplasms
  • Online Systems
  • Omentum
  • Observer Variation
  • Neoadjuvant Therapy
  • Kaplan-Meier Estimate